Kelzz
reacted to
$Arcutis Biotherapeutics(ARQT.US$ note timestamp in upper left then compare to trade start time listed!
3
Kelzz
reacted to
$Arcutis Biotherapeutics(ARQT.US$ Resume quotes at 17:15 And trading at 17:20
1
Kelzz
reacted to
$Arcutis Biotherapeutics(ARQT.US$
“Arcutis Biotherapeutics Announces FDA Approval Of Supplemental New Drug Application For Zoryve (Roflumilast)
Cream 0.15% To Treat Mild To Moderate Atopic Dermatitis In Adults And Children 6 And Older” - Benzinga
“Arcutis Biotherapeutics Announces FDA Approval Of Supplemental New Drug Application For Zoryve (Roflumilast)
Cream 0.15% To Treat Mild To Moderate Atopic Dermatitis In Adults And Children 6 And Older” - Benzinga
7
4
Kelzz
reacted to
$Clene(CLNN.US$ Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome 1 MINUTE AGO, 7:09 AM EDT VIA GLOBENEWSWIRE: CNM-Au8 demonstrated neuroprotective effects in an in vitro model of Rett Syndrome, a rare pediatric neurodevelopmental disease CNM-Au8 also demonstrated rescue of mitochondrial deficits in induced astrocytes derived from Rett patients Invited oral presentation and poster presented on June 19, 2024, at the International Rett Syndrome Foundatio...
2
4
Kelzz
reacted to
$Clene(CLNN.US$ Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting 2 MINUTES AGO, 7:00 AM EDT VIA GLOBENEWSWIRE - Survival analyses with CNM-Au8 30 mg treatment compared to matched PRO-ACT controls demonstrated improved survival up to 3.5 years post-baseline (hazard ratio: 0.431, p=0.0002) Average of 28% NfL reduction observed in an NfL respon...
5
3